Cargando…

Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis

BACKGROUND: The anti–human epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab improves outcomes in patients with node-positive HER2+ early breast cancer. Given trastuzumab’s high cost, we aimed to estimate its cost-effectiveness by heterogeneity in age and estrogen receptor (E...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leung, William, Kvizhinadze, Giorgi, Nair, Nisha, Blakely, Tony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4978494/ https://www.ncbi.nlm.nih.gov/pubmed/27504960 http://dx.doi.org/10.1371/journal.pmed.1002067

Ejemplares similares

Cancer care coordinators in stage III colon cancer: a cost-utility analysis
por: Blakely, Tony, et al.
Publicado: (2015)

A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity
por: Teng, Andrea M., et al.
Publicado: (2017)

Home modification to reduce falls at a health district level: Modeling health gain, health inequalities and health costs
por: Wilson, Nick, et al.
Publicado: (2017)

How much might a society spend on life-saving interventions at different ages while remaining cost-effective? A case study in a country with detailed data
por: Kvizhinadze, Giorgi, et al.
Publicado: (2015)

Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
por: Genuino, Anne Julienne, et al.
Publicado: (2019)

Health Benefits and Cost-Effectiveness From Promoting Smartphone Apps for Weight Loss: Multistate Life Table Modeling
por: Cleghorn, Christine, et al.
Publicado: (2019)

Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer
por: Hajjar, Ali, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
por: Tran, Phuong T., et al.
Publicado: (2020)

Why equal treatment is not always equitable: the impact of existing ethnic health inequalities in cost-effectiveness modeling
por: McLeod, Melissa, et al.
Publicado: (2014)

Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program
por: Pearson, Amber L, et al.
Publicado: (2014)

Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
por: Lluch-Gómez, J., et al.
Publicado: (2023)

Health system costs for individual and comorbid noncommunicable diseases: An analysis of publicly funded health events from New Zealand
por: Blakely, Tony, et al.
Publicado: (2019)

Patterns of Cancer Care Costs in a Country With Detailed Individual Data
por: Blakely, Tony, et al.
Publicado: (2015)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
por: McLaughlin, Shannon, et al.
Publicado: (2023)

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
por: Simoens, Steven, et al.
Publicado: (2021)

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
por: Ansaripour, Amir, et al.
Publicado: (2017)

How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?
por: Morganti, S., et al.
Publicado: (2022)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials
por: Viani, Gustavo A, et al.
Publicado: (2007)

Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis
por: Goldvaser, Hadar, et al.
Publicado: (2019)

Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis
por: Genuino, Anne Julienne, et al.
Publicado: (2019)

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
por: Dang, Chau, et al.
Publicado: (2022)

PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?
por: Pondé, Noam, et al.
Publicado: (2019)

Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab
por: McGuire, Andrew, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Trastuzumab in the Adjuvant Treatment for Early Breast Cancer
por: Aboutorabi, Ali, et al.
Publicado: (2015)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
por: Ishimine, Yu, et al.
Publicado: (2015)

The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer
por: Delgado, J., et al.
Publicado: (2021)

Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer
por: Gershon, Noga, et al.
Publicado: (2019)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
por: Loibl, Sibylle, et al.
Publicado: (2022)

Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy
por: Cao, Lu, et al.
Publicado: (2016)

Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
por: Sardesai, Sagar, et al.
Publicado: (2020)

Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials
por: Yin, Wenjin, et al.
Publicado: (2011)

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
por: Moreno-Aspitia, Alvaro, et al.
Publicado: (2013)

Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: The Nvwa study
por: Li, Junjie, et al.
Publicado: (2018)

Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer
por: Rojas, Luis, et al.
Publicado: (2020)

HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma
por: Portier, Bryce P, et al.
Publicado: (2013)

Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer
por: Yang, Hai-Yuan, et al.
Publicado: (2017)

Concurrent administration of trastuzumab and anthracyclines as adjuvant regimen for HER2-positive breast cancer: a randomised controlled trial
por: Shen, Songjie, et al.
Publicado: (2017)

Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab
por: Jacquinot, Quentin, et al.
Publicado: (2022)

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial
por: Guarneri, Valentina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vuq2nmmvqc7kdtcngogsdk5nco